Article
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis.
Targeted oncology - 1 Sept 2022
Rimini Margherita, Burgio Valentina, Antonuzzo Lorenzo, Rimassa Lorenza, Oneda Ester, Lavacchi Daniele, Personeni Nicola, Ratti Francesca, Pedica Federica, Della Corte Angelo, Persano Mara, De Cobelli Francesco, Aldrighetti Luca, Scartozzi Mario, Cascinu Stefano, Casadei-Gardini Andrea
Abstract excerpt
BACKGROUND: The results of the phase III ClarIDHy trial have led to US FDA approval of ivosidenib as a therapeutic option for patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring isocitrate dehydrogenase 1 (IDH1) mutations. OBJECTIVE: In this study, we report the first real-world experience including eight patients with previously treated locally advanced or metastatic IDH1-mutated CCA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.